Adrian Sacher, M.D. is currently presenting at the IASLC’s #TTLC23 the topic: Combination IO and targeted Therapy. #LCSM

Our terrific CTR editor at The Oncologist! The Oncologist

Incredible ORR 62% in GDC-6036 combo w/ cetuximab for KRAS G12C mut colorectal cancer which represents ~3% of the US patient popn. #AACR23 Looking forward to drug development targeting KRAS G12D/V that represents ~22% of patients w/ colorectal cancer!

Really amazing data on GDC-6036 plus cetuximab in KRAS G12C metastatic colon cancer - ORR 62% !!! More potent KRAS G12C inhibitors make for more effective combos & better options for patients. #AACR23 KRASKickers

Upfront Atezolizumab Poses Lower Risk of Hyperprogression in NSCLC cancertherapyadvisor.com/home/cancer-to…

Canadian Consensus Recommendations on the Management of KRASm G12C #NSCLC #KRAS 🫁 🔻 doi.org/10.3390/curron…

🔬 Dr. Adrian Sacher, M.D.'s mission is to comprehend the body's immune response to cancer cells. With LCFA's support, he explores novel therapies that may transform treatment approaches. 🌱 #Livingwithlungcancer #LCFAmerica #LCFAResearch #WLCD23 #lungcancer bit.ly/44Czi5C

🌟 Dr. Adrian Sacher, M.D.'s research uncovers potential treatments for lung cancer patients facing drug resistance. With LCFA backing, he takes crucial steps towards a brighter future for those battling lung cancer. #Livingwithlungcancer #WLCD23 #lungcancer bit.ly/44Czi5C

The support of LungCancerAmerica and patients & their families has been essential to our ongoing work to end lung cancer. Thank you so much - great things to come!

Exciting new clinical findings from Adrian Sacher, M.D. Princess Margaret Cancer Centre UHN Research demonstrating potential of targeting KRAS

Pleased to participate in #Coalition4CdnResearch press conference with all Canadian advocacy groups coming together to call on the federal government to invest in research. Chrystia Freeland @KirstyDuncanMP Justin Trudeau

Next up #TTLC24 Targeted Therapies: KRAS, BRAF, SHP2, SOS1 kicks off w/ Ferdinandos Skoulidis Mary-Tiffany Adannia Oduah M.D. Mark Awad Alex Spira, M.D. Suki Kaur Padda Kristen A. Marrone, MD Dr. Nagla Abdel Karim Adrian Sacher, M.D. Natalie Vokes!

Not one, not 2, but 3 lung cancer plenaries at #ASCO24 ! Early telemed pall care, the LAURA trial of consolidation osimertinib after CRT for stage 3 EGFR non small cell lung cancer & the ADRIATIC trial of consolidation immunotherapy after CRT for small cell lung cancer! #lcsm

Excited for #ASCO24! While disease specific content is best found in oral session dedicated to a disease group, explore thematic Clinical Science Symposia that are a highlight - such as the special session on #KRAS In #NSCLC 📍Hall B1, Sat, Jun 1 Tony Mok Adrian Sacher, M.D. Kathryn C. Arbour

Excellent summary of #KRASG12C trials in the metastatic NSCLC space by Adrian Sacher, M.D. ASCO #ASCO24 ✨ 2L tx TKI v. Docetaxel ✨ combination TKI + IO ✨ combination with chemo ✨ combination with EGFR Lot if interest in this space and congrats to all the authors OncoAlert

Hot off the presses and #ESMO24 podium: Adrian Sacher, M.D. UHN Research presents initial findings of the CNS-penetrant MTA-cooperative PRMT5 inhibitor AMG 193 in patients with solid tumors 👉🏻 aacrjournals.org/cancerdiscover…

Hans Prenen #ESMO24 concomitant paper: Adrian Sacher, M.D. presents the First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor at today's Presidential Symposium Hans Prenen

AMG 193 Shows Preliminary Clinical Activity in MTAP-Deleted Solid Tumors Adrian Sacher, M.D. Princess Margaret Cancer Centre Temerty Medicine University of Toronto #ESMO24 #ESMO2024 #MedTwitter onclive.com/view/amg-193-s…

It was a pleasure to spend the day ASCO planning the metastatic NSCLC program with this amazing group (missing Toby Campbell). Looking forward to an exciting #ASCO25 !